Grants for Small business (Over $500K)

Expected Impact: The action under this topic is expected to achieve the following impacts and contribute to the following EU policies/initiatives: deliver innovative, early technology solutions that contribute to addressing strategic unmet public health needs across multiple therapy areas to improve prevention, early diagnosis, and treatment; leverage the unique network and scale of IHI JU members to create a pipeline to support innovative startups in the health industry, fully integrated into European initiatives in support of start-ups and entrepreneurship; drive early cross-sector health R&D and innovation to strengthen the European healthcare industry’s global competitiveness, contributing to the EU Industrial Strategy and Pharmaceutical Strategy objectives; create a sustainable network of European healthcare incubators to guide and support highly talented and innovative early-stage companies; harness digital health and data-sharing technologies (e.g., AI and big data) to enable interoperable health solutions, contributing to the European Health Data Space (EHDS) and improved evidence based care;- the action should generate a portfolio of early‑stage companies that have…

Expected Outcome: Proposals are expected to contribute to the following outcomes: Steer a European agenda to catalyse the development of a full software defined and hardware-enabled vehicle AD stack “built in Europe”, from onboard-compute architecture up to software in-vehicle up to the cloud. Establish structured intersectoral linkages between software, AI/data, hardware and deployment actors, ensuring that architectural decisions in the European AD stack are aligned across computing platforms, AI models, validation frameworks and real-world deployment environments. Promote a European R&I roadmap establishing pathways for the accelerated development of a European AI-powered AD stack, notably in close liaison with the relevant ECAVA Working Groups and relevant OSS initiatives. Ensure the engagement of key stakeholders across the Automotive value chain (including relevant OSS initiatives) toward an open-source software autonomous driving stack, including required industrial partners (such as OEMs, suppliers, tool-providers), and innovative R&I stakeholders (RTOs, universities, start-ups. If useful, already existing OSS AD stack initiatives together with the reference stacks (as…

Expected Outcome: Projects should contribute to all of the following expected outcomes: Deepened knowledge of specific factors favouring the growth of creative startups [1] , in particular those with potential for disruptive innovation [2] and/or cross-sectorial innovation impacts, is made available and promoted to policymakers, investors, funding- and enterprise support bodies. Effective methods to favour the growth of creative startups, in particular those with potential for disruptive innovation and/or cross-sectorial innovation impacts, are developed, tested and put in practice by industry, investors, funding- and enterprise support bodies, and relevant decision makers. Examples of creative startups scaling up and/or engaging in disruptive innovation are made available, with a view to increase the visibility and recognition of the innovative power of Europe’s creative startups. In addition, proposals should contribute to at least one of the following expected outcomes, depending on the option chosen (a or b below): The effectiveness of the methods developed is demonstrated by at least one creative startup supported via the action becoming a scaleup [3] in a Member State or an…

Expected Outcome: Project results are expected to contribute to the following outcomes: Increased commercialisation of academic research results, by facilitating access for industry, startups and scaleups to the intellectual assets of academic research; Strengthened collaboration between industry and academia, reflected in an increased number of technology transfer deals and joint R&D projects resulting in market-ready innovations; Introduced more startup friendly intellectual asset transfer/licensing policies in universities/research and higher education institutions/RTOs; Increased number of spinoffs by enabling researchers to overcome the barriers to commercialising their intellectual assets; Reduced transaction costs related to Intellectual Property Rights (IPR) negotiations by establishing more standardised asset transfer policies across universities/research and higher education institutions/RTOs; Optimised transfer/licensing processes by universities/research and higher education institutions/RTOs based on grouping intellectual assets in portfolios that can be commercialised in package deals that are more attractive for industry and investors. Scope: Academic knowledge…

Expected Outcome: This action will support and accelerate the development and adoption of European and international standards for quantum technologies, enhancing interoperability quality/reliability assurance, and trust in quantum systems. It will strengthen Europe's leadership in the global quantum standardisation landscape and ensure that European industrial and research priorities are well represented and integrated into emerging standards. Expected outcomes include: Delivery of concrete, EU-relevant pre-normative standards and technical specifications across quantum computing, communication, and sensing. Substantial contribution of European stakeholders, notably SMEs and start-ups in international standardisation bodies (e.g., ISO/IEC, ITU-T, ETSI), with alignment to EU industrial strategies. Promotion of cross-sectoral interoperability through standardised interfaces, control protocols, reliability in operating conditions and benchmarking methodologies, reducing market fragmentation and technical barriers. Creation of practical support tools such as user guidelines, training modules, and best practices to accelerate the uptake and implementation of quantum…

Expected Outcome: Project results are expected to contribute to some or all of the following expected outcomes: A community of EU civil security practitioners with common user/functional needs for innovative technology solutions is identified, supported by an industrial base, in particular SMEs and Startups, to access the public procurement market and scale up their business; Procurers facilitated the commercialisation of the innovative solutions developed by their successful suppliers by providing them with first customer references for the validation and first pilot deployment; Tested and validated capacity of EU technology and industrial base to develop and produce technology prototypes that meet the diverse needs of the EU user community, regardless of their gender, age and ability; Improved delineation of the EU market (including demand and supply) for innovative civil security systems that can articulate alternative options for uptake in function of different industrialisation needs, commercialisation needs, acquisition needs, deployment needs and additional funding needs (beyond R&I funding). Scope: As past experience shows that pre-commercial procurement opens up the…

FindBusinessSupport.gov.scot gives an overview of grants, loans, funding, advice and other support available to businesses in Scotland, offered by over 100 Scottish public sector organisations, conveniently in one place. Information is available for businesses of all sizes and sectors, from start-ups and sole traders to large enterprises and includes support for social enterprises.

The purpose of this Notice of Funding Opportunity (NOFO) is to leverage NICHD clinical research Network infrastructure relevant to infants, children, women, pregnant and lactating women, and persons with disabilities to conduct innovative, multisite, investigator-initiated clinical trials and observational studies. This NOFO will utilize a bi-phasic (UG3/UH3), milestone-driven mechanism consisting of a start-up phase (UG3) and a full enrollment and clinical trial implementation phase (UH3). Applications submitted in response to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases. A UG3 project (phase I) that meets its milestones will be administratively considered by NICHD and prioritized for transition to the UH3 award (phase II). This NOFO provides an opportunity to leverage NICHD clinical research Network infrastructure as a platform for investigator-initiated innovative hypotheses by any investigator in the extramural community. Applications must be submitted as investigator-initiated, multi-Project Director/Principal Investigator (PD/PI) grant applications in conjunction with the respective NICHD-supported Network Data Coordinating Center (DCC), or equivalent as determined by the NICHD.